Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Drop in Short Interest

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totaling 37,653 shares, a drop of 35.3% from the March 15th total of 58,172 shares. Based on an average trading volume of 26,772 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.8% of the company’s shares are sold short.

Evaxion A/S Trading Down 0.8%

NASDAQ:EVAX traded down $0.03 during trading hours on Tuesday, reaching $4.11. 9,686 shares of the company were exchanged, compared to its average volume of 44,678. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The firm has a market cap of $34.24 million, a price-to-earnings ratio of -3.11 and a beta of 0.19. Evaxion A/S has a 52-week low of $1.25 and a 52-week high of $12.15. The stock has a 50 day simple moving average of $3.56 and a 200 day simple moving average of $4.78.

Hedge Funds Weigh In On Evaxion A/S

Large investors have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC purchased a new position in Evaxion A/S during the fourth quarter worth approximately $72,000. Northwestern Mutual Wealth Management Co. purchased a new position in Evaxion A/S during the fourth quarter worth approximately $38,000. Finally, Wesbanco Bank Inc. purchased a new position in Evaxion A/S during the fourth quarter worth approximately $48,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on EVAX shares. JonesTrading started coverage on shares of Evaxion A/S in a research note on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price for the company. Maxim Group started coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Wall Street Zen cut shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.